Chapter 1. Lipoprotein Physiology Chapter 2. Epidemiology of Blood Lipids and Lipoproteins Chapter 3. Lipoprotein(a) Chapter 4. Lipoproteins and Cardiovascular Disease Risk Chapter 5. Detection and Treatment of Children and Adolescents with Dyslipidemia Chapter 6. Type 2 Diabetes Mellitus and Dyslipidemia Chapter 7. Type 1 Diabetes Mellitus and Dyslipidemia Chapter 8. Dyslipidemia in Chronic Kidney Disease and Nephrotic Syndrome Chapter 9. Dyslipidemia in HIV-infected Patients Chapter 10. Monogenic Hypercholesterolemia Chapter 11. Primary Hypertriglyceridemia Chapter 12. Genetic Disorders of HDL Metabolism Chapter 13. Sitosterolemia and Other Rare Sterol Disorders Chapter 14. Genetic Abetalipoproteinemia & Hypobetalipoproteinemia Chapter 15. Drug-induced Dyslipidemia Chapter 16. Lipodystrophies and Dyslipidemias Chapter 17. Novel Genes for Dyslipidemias: Genome-Wide Association Studies Chapter 18. Perspectives on Cholesterol Guidelines Chapter 19. Nutrition and Coronary Heart Disease Prevention Chapter 20. Phytosterol Therapy Chapter 21. N-3 Fatty Acids: Role in Treating Dyslipidemias and Preventing Cardiovascular Disease Chapter 22. Polyphenols for Cholesterol Management Chapter 23 - Dietary Supplements for Cholesterol Management Chapter 24. Statins: Risk-Benefits and Role in Treating Dyslipidemias Chapter 25. Fibrates: Risk-Benefits and Role in Treating Dyslipidemias Chapter 26. Niacin: Risk-Benefits and Role in Treating Dyslipidemias Chapter 27. Bile Acid Sequestrants: Risk-Benefits and Role in Treating Dyslipidemias Chapter 28. Cholesterol Absorption Inhibitor-Ezetimibe: Risk-Benefits and Role in Treating Dyslipidemias Chapter 29. Low Density Lipoprotein (LDL) Apheresis Chapter 30. Novel Lipid Lowering Agents Skryť popis